Heart Attack

Clinical Trial Finder

Many patients with heart disease are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Efficacy and Safety of ICD Implantation in the Elderly

Conditions:   Cardiomyopathy;   Coronary Artery Disease;   Congestive Heart Failure;   Myocardial Infarction
Interventions:   Device: Implantable Cardioverter Defibrillator;   Other: Optimal standard of care
Sponsor:   Department of Veterans Affairs
Not yet recruiting - verified April 2014

Mi-RNAs and Specificity of Hs-TnT in Symptomatic ED Patients

Conditions:   Coronary Artery Disease;   Myocardial Infarction
Intervention:  
Sponsors:   University Hospital Heidelberg;   German Heart Research Foundation
Not yet recruiting - verified April 2014

Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides

Condition:   ANCA-associated Primary Necrotizing Vasculitides
Interventions:   Drug: Rosuvastatin;   Drug: Placebo
Sponsor:   Assistance Publique - Hôpitaux de Paris
Not yet recruiting - verified April 2014

Study to Detect Biomarker Gradients in Coronary Arteries Using the Liquid Biopsy System

Condition:   Coronary Heart Disease
Intervention:  
Sponsors:   PlaqueTec Ltd;   Papworth Hospital NHS Foundation Trust
Not yet recruiting - verified April 2014

Carnitine for the Treatment of Atherosclerosis.

Condition:   Metabolic Syndrome
Interventions:   Dietary Supplement: L-carnitine capsules;   Dietary Supplement: Lactose capsules
Sponsors:   Queen's University;   Heart and Stroke Foundation of Canada
Not yet recruiting - verified April 2014

Rivaroxaban for Antiphospholipid Antibody Syndrome

Condition:   Antiphospholipid Antibody Syndrome
Intervention:   Drug: Rivaroxaban
Sponsors:   St. Joseph's Healthcare Hamilton;   Heart and Stroke Foundation of Canada;   Bayer;   Hamilton Health Sciences Corporation;   Jewish General Hospital;   University of Alberta;   The Ottawa Hospital;   Queen Elizabeth II Health Sciences Centre
Not yet recruiting - verified April 2014

Renal Denervation in Patients With Heart Failure With Normal LV Ejection Fraction

Conditions:   Heart Failure, Diastolic;   Hypertension
Intervention:   Procedure: Renal denervation + medical therapy
Sponsor:   InCor Heart Institute
Recruiting - verified April 2014

DIAMOND - Dual Antiplatelet Therapy to Reduce Myocardial Injury

Condition:   Coronary Artery Disease
Interventions:   Drug: Ticagrelor;   Drug: Placebo
Sponsors:   University of Edinburgh;   AstraZeneca
Not yet recruiting - verified April 2014

POST-dilatation to Improve Outcomes in Acute STEMI Patients Undergoing Primary With OCT Assessment

Condition:   Acute Myocardial Infarction
Interventions:   Device: post-dilatation with a Quantum Maverick balloon;   Device: manual thrombus aspiration + Promus Element stent implant
Sponsors:   Second Affiliated Hospital, School of Medicine, Zhejiang University;   The First Hospital of Nanjing Medical University;   Shanghai East Hospital;   Ningbo First Hopital
Not yet recruiting - verified April 2014

Short-term Dual Anti Platelet Therapy in Patients With ACS Treated With the COMBO Dual-therapy Stent

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Treatment 3 months DAPT;   Drug: Treatment 12 months DAPT
Sponsor:   Diagram B.V.
Not yet recruiting - verified April 2014

PATient Navigator to rEduce Readmissions

Conditions:   Chronic Obstructive Pulmonary Disease;   Heart Failure;   Sickle Cell Disease;   Myocardial Infarction;   Pneumonia;   Vascular Procedures
Interventions:   Behavioral: Hospital usual care;   Behavioral: Patient Navigator;   Behavioral: Peer-led telephone support line
Sponsors:   University of Illinois at Chicago;   Patient-Centered Outcomes Research Institute (PCORI);   University of Illinois at Urbana-Champaign;   Society of Hospital Medicine;   COPD Foundation;   University of Kentucky;   Mended Hearts;   American Heart Association;   Sickle Cell Disease Association of Illinois;   AcademyHealth;   The National Association of Social Workers Foundation;   Respiratory Health Association of Metropolitan Chicago;   University of Illinois Sickle Cell Patient Council;   National Jewish Health;   Olmsted Medical Center;   Baystate Medical Center;   Department of Veterans Affairs
Not yet recruiting - verified April 2014

Improving Adherence to Medication After Coronary Artery Bypass Surgery (CABG) in Older Adults

Condition:   Coronary Artery Bypass Grafting (CABG) Surgery
Interventions:   Behavioral: Motivational Interviewing (MI;   Behavioral: volitional intervention;   Behavioral: Routine discharge counseling
Sponsor:   Qazvin University Of Medical Sciences
Recruiting - verified April 2014

Outcomes of Angiotensin Converting Enzyme Inhibitor Management Strategies Prior to Coronary Artery Bypass

Condition:   Coronary Artery Disease
Interventions:   Drug: ACE/ARB continuation;   Drug: ACE/ARB withdrawal
Sponsor:   University of Alberta
Recruiting - verified April 2014

Elite Controller and ART-treated HIV+ Statin Versus ASA Treatment Intervention Study

Condition:   Immunodeficiency Virus, Human
Interventions:   Drug: Aspirin 81 mg table;   Drug: Atorvastatin 40 mg
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2013

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)

Conditions:   Pulmonary Embolism;   Thromboembolism;   Thrombosis;   Venous Thrombosis;   Venous Thromboembolism
Interventions:   Drug: BAY 59-7939;   Drug: BAY 59-7939;   Drug: ASA
Sponsor:   Bayer
Recruiting - verified April 2014

Antiplatelet Therapy Following Stent Implantation

Conditions:   Acute Myocardial Infarction;   Coronary Syndrome;   Angina, Unstable
Intervention:  
Sponsor:   Elpen Pharmaceutical Co. Inc.
Recruiting - verified January 2014

BIOFLOW III Satellite-Italy

Condition:   Coronary Artery Diseases
Intervention:  
Sponsor:   Biotronik Italia S.p.A.
Recruiting - verified January 2014

BIOFLOW III Satellite-ELADIS

Condition:   Coronary Artery Disease
Intervention:  
Sponsor:   C.E.M. Biotronik, S.A.
Recruiting - verified February 2014

A Trial to Evaluate a New Strategy in the Functional Assessment of 3-vessel Disease Using the SYNTAX II Score in Patients Treated With PCI

Conditions:   Heart Diseases;   Cardiovascular Diseases;   3 Vessel Coronary Artery Disease
Interventions:   Device: Coronary stent;   Radiation: Multi Slice Computed Tomography;   Device: instantaneous wave-free ratio;   Device: Fractional flow reserve;   Device: Intravascular Ultrasound
Sponsors:   ECRI bv;   Boston Scientific Corporation;   Volcano Corporation
Recruiting - verified April 2014

A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Ticagrelor 90 mg;   Drug: Ticagrelor placebo
Sponsor:   AstraZeneca
Recruiting - verified April 2014

Cardiovascular Outcomes Following Treatment With Ertugliflozin in Participants With Type 2 Diabetes Mellitus and Established Vascular Disease (MK-8835-004)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Recruiting - verified April 2014

Hip Fracture Impact on Vascular Events In Noncardiac Surgery patIents: a cOhort evaluatioN (Hip VISION): Pilot Study

Condition:   Hip Fractures
Intervention:  
Sponsor:   Population Health Research Institute
Active, not recruiting - verified April 2014

The Evaluation Of PF-04950615 (RN316) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: PF-04950615;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified April 2014

The Evaluation Of PF-04950615 (RN316), In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: PF-04950615;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified April 2014

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec;   Drug: insulin glargine
Sponsor:   Novo Nordisk A/S
Recruiting - verified April 2014

Does Continued Use of Clopidogrel Into Surgery Cause Increased Perioperative Bleeding?

Condition:   Clopidogrel
Interventions:   Drug: Clopidogrel;   Drug: Discontinue Clopidogrel
Sponsors:   Mount Sinai School of Medicine;   Doris Duke Charitable Foundation
Recruiting - verified April 2014

HsTnT in Stable Coronary Artery Disease

Condition:   Coronary Artery Disease
Intervention:   Other: Progress of CHD
Sponsors:   University Hospital Heidelberg;   AstraZeneca
Active, not recruiting - verified April 2014

The Surgery After Stenting (SAS) Registry

Conditions:   PERCUTANEOUS CORONARY INTERVENTION;   STENTS;   SURGERY
Intervention:  
Sponsors:   Arcispedale Santa Maria Nuova-IRCCS;   Italian Society of Invasive Cardiology;   Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO)
Recruiting - verified September 2013

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Phenprocoumon
Sponsor:   Bayer
Recruiting - verified April 2014

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Warfarin
Sponsor:   Bayer
Recruiting - verified April 2014

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Acenocoumarol
Sponsor:   Bayer
Recruiting - verified April 2014

GLORIA-AF Registry Program (Phase II/III)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified April 2014

CXCR4 Antagonism for Cell Mobilisation and Healing in Acute Myocardial Infarction (CATCH-AMI)

Condition:   Large Reperfused ST-Elevation Myocardial Infarction
Interventions:   Drug: POL6326;   Drug: Placebo
Sponsor:   Polyphor Ltd.
Recruiting - verified April 2014

Interleukin-1 Blockade With Canakinumab to Improve Exercise Capacity in Patients With Chronic Systolic Heart Failure and Elevated Hs-CRP

Conditions:   Prior Acute Myocardial Infarction;   Evidence of Systemic Inflammation (C Reactive Protein Plasma >2 mg/l);   Reduced Left Ventricle Ejection Fraction (<50%);   Symptoms of Heart Failure (NYHA Class II-III)
Interventions:   Other: Cardiopulmonary exercise test;   Other: Echocardiogram
Sponsors:   Virginia Commonwealth University;   Novartis Pharmaceuticals
Active, not recruiting - verified April 2014

Application for Self-Monitoring of Cardiovascular Risk

Condition:   Coronary Artery Disease Which Requires Percutaneous Coronary Intervention(Balloon and/or Stent Treatment).
Intervention:   Device: Self Monitoring Software Application
Sponsor:   Mayo Clinic
Recruiting - verified April 2014

Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation Patients

Conditions:   Stroke,;   Embolism
Intervention:   Other: Rivaroxaban ( Xarelto, BAY59-7939)
Sponsor:   Bayer
Recruiting - verified April 2014

Study Of Diabetic Nephropathy With Atrasentan

Condition:   Diabetic Nephropathy
Interventions:   Drug: Atrasentan;   Drug: Placebo
Sponsor:   AbbVie
Recruiting - verified April 2014

Cerebral Oximetry and Perioperative Outcome in Non-Cardiac Surgery

Conditions:   High Risk Non-cardiac Surgery;   Death;   Delirium;   Kidney Injury;   Myocardial Infarction;   Respiratory Failure;   Postoperative Infection
Intervention:   Other: Observational study
Sponsors:   University of Manitoba;   Canadian Anesthesia Research Foundation;   University of Manitoba Department of Anesthesia
Not yet recruiting - verified April 2014

BIOFLOW-III Belgium Satellite Registry

Conditions:   Coronary Artery Disease;   Myocardial Ischemia
Intervention:  
Sponsor:   Biotronik Belgium NV
Recruiting - verified April 2013

The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome

Conditions:   Antiphospholipid Syndrome;   Endothelial Dysfunction;   Hyperuricemia;   Gout;   Metabolic Syndrome
Intervention:  
Sponsor:   National Taiwan University Hospital
Recruiting - verified April 2014

Sleep to Lower Elevated Blood Pressure

Conditions:   Hypertension;   Sleep Disorders;   Insomnia;   Cardiovascular Diseases
Intervention:   Behavioral: Online Sleep Education
Sponsors:   University College Hospital Galway;   Health Research Board, Ireland
Recruiting - verified April 2014

The Elderly ACS II Trial

Conditions:   Acute Coronary Syndrome;   Coronary Arteriosclerosis;   Myocardial Ischemia;   Cardiovascular Diseases
Interventions:   Drug: prasugrel;   Drug: Clopidogrel
Sponsors:   Arcispedale Santa Maria Nuova-IRCCS;   ANMCO Italian Association of Hospital Cardiologist;   Italian Society of Invasive Cardiology
Recruiting - verified April 2014

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Condition:   Dyslipidemia
Interventions:   Device: Evolocumab (AMG 145);   Device: Placebo;   Drug: Effective statin therapy
Sponsor:   Amgen
Recruiting - verified April 2014

A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy

Condition:   Atrial Fibrillation
Interventions:   Drug: rivaroxaban;   Drug: uninterrupted vitamin K antagonist (VKA)
Sponsor:   Janssen Scientific Affairs, LLC
Recruiting - verified April 2014

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Condition:   Cardiovascular Disease, Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK-3102;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified April 2014

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified April 2014

BIOFLOW-III Austria Satellite Registry

Conditions:   Coronary Artery Disease;   Myocardial Ischemia
Intervention:  
Sponsor:   Biotronik Vertriebs-GmbH
Recruiting - verified April 2013

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: alirocumab SAR236553 (REGN727);   Other: placebo
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified April 2014

Danhong Injection in the Treatment of Chronic Stable Angina

Condition:   Chronic Stable Angina
Interventions:   Drug: Danhong injection;   Other: Standard medical care;   Drug: Placebo
Sponsors:   China Academy of Chinese Medical Sciences;   China: State Food and Drug Administration
Recruiting - verified April 2014

Invasive vs Conservative Strategies in Non-ST-elevation Acute Coronary Syndrome and Comorbidities

Condition:   Acute Coronary Syndrome
Intervention:   Procedure: Coronary angiogram
Sponsors:   University of Valencia;   Instituto de Salud Carlos III
Active, not recruiting - verified April 2014

Omacor Plus Standard Therapies In Post Myocardial Infarction (MI) Subjects Evaluation: The OPTIMISE Observational Study

Condition:   Myocardial Infarction (MI)
Intervention:  
Sponsor:   Abbott
Active, not recruiting - verified April 2014

ProspEctive First Evaluation in Chest Pain Trial

Conditions:   Chest Pain;   Shortness of Breath;   Suspected Acute Coronary Syndrome
Interventions:   Procedure: Coronary CT Angiography;   Procedure: Stress Test
Sponsor:   St. Luke's-Roosevelt Hospital Center
Recruiting - verified May 2012

Primary Care Providers Use of a Gene Expression Test in Coronary Artery Disease Diagnosis

Conditions:   Chest Pain;   Cardiovascular Disease
Intervention:  
Sponsor:   CardioDx
Completed - verified April 2014

Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.

Condition:   Smoking Cessation
Interventions:   Drug: placebo;   Drug: varenicline tartrate;   Drug: bupropion hydrochloride;   Drug: Nicotine Replacement Therapy Patch
Sponsor:   Pfizer
Recruiting - verified April 2014

GLORIA-AF Registry Program - Second and Third Phases

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified April 2014

Risk Factors for Coronary Artery Calcification and Left Ventricular Hypertrophy in Hemodialysis Patients

Condition:   End Stage Renal Disease
Intervention:  
Sponsors:   University of Alberta;   Massachusetts General Hospital
Recruiting - verified April 2014

Clearance Of Mucus In Stents

Conditions:   Lung Neoplasms;   Respiratory Failure;   Pneumonia;   Acute Coronary Syndromes;   Unstable Angina;   Myocardial Infarction;   Cardiac Arrhythmia;   Thromboembolic Disease
Interventions:   Other: Normal Saline;   Other: Sodium Bicarbonate
Sponsor:   M.D. Anderson Cancer Center
Recruiting - verified April 2014

A Study of RoActemra/Actemra (Tocilizumab) in Comparison to Etanercept in Patients With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors

Condition:   Cardiovascular Disease, Rheumatoid Arthritis
Interventions:   Drug: tocilizumab [RoActemra/Actemra];   Drug: etanercept
Sponsor:   Hoffmann-La Roche
Active, not recruiting - verified April 2014

Xenon Compared to Sevoflurane and Total Intravenous Anaesthesia for Coronary Artery Bypass Graft Surgery

Conditions:   Coronary Artery Disease;   General Anesthetic Drug Allergy;   Coronary Artery Bypass Graft Surgery
Interventions:   Drug: Xenon;   Drug: Sevoflurane;   Drug: Propofol
Sponsors:   Air Liquide Santé International;   Orion Corporation, Orion Pharma
Completed - verified April 2014

REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification

Condition:   Atherosclerotic Cardiovascular Disease
Interventions:   Drug: anacetrapib;   Drug: placebo anacetrapib
Sponsors:   University of Oxford;   Merck Sharp & Dohme Corp.
Active, not recruiting - verified April 2014

EXCEL Clinical Trial

Conditions:   Chronic Coronary Occlusion;   Unprotected Left Main Coronary Artery Disease;   Stent Thrombosis;   Vascular Disease;   Myocardial Ischemia;   Coronary Artery Stenosis;   Coronary Disease;   Coronary Artery Disease;   Coronary Restenosis
Interventions:   Device: Percutaneous Coronary Intervention;   Procedure: CABG
Sponsor:   Abbott Vascular
Active, not recruiting - verified April 2014

Trial of Atorvastatin on the Persistent Coronary Aneurysm in Children With Kawasaki Disease

Conditions:   Kawasaki Disease;   Aneurysm, Coronary
Intervention:   Drug: Atorvastatin
Sponsors:   National Taiwan University Hospital;   National Science Council, Taiwan
Recruiting - verified April 2014

Anticoagulation in Stent Intervention

Conditions:   Atrial Fibrillation;   Stroke
Interventions:   Drug: Acetylsalicylic Acid + clopidogrel + acenocoumarol;   Drug: Acetylsalicylic Acid + clopidogrel
Sponsor:   Hospital Universitari Vall d'Hebron Research Institute
Recruiting - verified April 2014

PeriOperative ISchemic Evaluation-2 Trial

Condition:   Cardiovascular Disease
Interventions:   Drug: Active Clonidine;   Drug: Placebo Clonidine;   Drug: Active ASA;   Drug: Placebo ASA
Sponsors:   McMaster University;   Hamilton Health Sciences Corporation
Active, not recruiting - verified April 2014

Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in European Patients With Ankylosing Spondylitis (MK-0663-163)

Condition:   Ankylosing Spondylitis
Intervention:  
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified April 2014

Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation Post Trial Observational Study

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   The George Institute;   Servier
Completed - verified April 2014

BAY81-8781, I.V. Aspirin in the Indication of Acute Coronary Syndrome (ACS)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Acetylsalicylic acid (Aspirin, BAY 81-8781);   Drug: Acetylsalicylic acid (Aspirin, BAY 81-8781);   Drug: Acetylsalicylic acid (Aspirin, BAY 81-8781)
Sponsor:   Bayer
Recruiting - verified April 2014

Patient-Centered Adherence Intervention After Acute Coronary Syndrome (ACS) Hospitalization

Condition:   Acute Coronary Syndrome
Interventions:   Behavioral: Intervention;   Behavioral: Usual care
Sponsor:   Department of Veterans Affairs
Completed - verified April 2014

Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy

Conditions:   HIV;   Hyperlipidemia;   Hypertriglyceridemia;   HIV Infections
Intervention:   Drug: raltegravir
Sponsors:   The Miriam Hospital;   Tufts Medical Center;   Merck Sharp & Dohme Corp.
Completed - verified October 2013

A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.

Condition:   Anemia
Interventions:   Drug: methoxy polyethylene glycol-epoetin beta [Mircera];   Drug: methoxy polyethylene glycol-epoetin beta [Mircera];   Drug: ESAs (darbepoetin alfa, epoetin alfa or epoetin beta)
Sponsor:   Hoffmann-La Roche
Active, not recruiting - verified April 2014

The VA Diabetes Trial Follow-up Study (VADT-FS)

Conditions:   Diabetes;   Glycemic Control
Intervention:  
Sponsor:   Department of Veterans Affairs
Active, not recruiting - verified April 2014

Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism

Condition:   Venous Thrombosis
Interventions:   Drug: Enoxaparin;   Drug: warfarin;   Drug: Placebo for apixaban;   Drug: Placebo for enoxaparin;   Drug: Placebo for warfarin;   Drug: apixaban
Sponsors:   Bristol-Myers Squibb;   Pfizer
Completed - verified April 2014

Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome

Condition:   Antiphospholipid Syndrome
Intervention:  
Sponsor:   Duke University
Recruiting - verified February 2014

Causes and Natural History of Dyslipidemias

Condition:   Dyslipidemias
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2014

Hypertension Intervention Nurse Telemedicine Study (HINTS)

Condition:   Hypertension
Interventions:   Behavioral: Nurse Behavioral intervention with Home BP Telemonitoring;   Behavioral: Nurse Medication Management with Home BP Telemonitoring;   Behavioral: Nurse Combined intervention with Home BP Telemonitoring
Sponsor:   Department of Veterans Affairs
Completed - verified April 2014

Web-Enhanced Guideline Implementation for Post MI CBOC Patients

Conditions:   Myocardial Infarction;   Comorbidity
Intervention:   Behavioral: VA MI Plus Interactive
Sponsor:   Department of Veterans Affairs
Completed - verified April 2014

Evaluation of Lipoproteins

Conditions:   Hyperlipidemia;   Hyperlipoproteinemia;   Hypolipoproteinemia
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2014

Get CardioSmart

You're Invited